Polaris Market Research today announced findings from its latest report, projecting the global Arbovirus Testing Market to grow from USD 1.31 billion in 2025 to USD 1.98 billion by 2034, at a CAGR of 4.70%. The report profiles 10 leading companies across segments spanning test type, arboviral disease, end-use, and region.

Analyst Commentary on Arbovirus Testing Market Growth

"Climate change and expanding vector ranges are pushing dengue, chikungunya, Zika, and West Nile virus into regions that historically saw few cases, and diagnostic infrastructure is racing to keep pace," said a Senior Analyst at Polaris Market Research. "Buyers evaluating testing platforms should prioritize vendors investing in rapid, isothermal molecular assays, since faster turnaround is becoming a key differentiator in outbreak response."

Arbovirus Testing Market Statistics at a Glance

• 2025 Market Size: USD 1.31 Billion
• 2026 Market Estimate: USD 1.43 Billion
• 2034 Projected Size: USD 1.98 Billion
• CAGR (2026–2034): 4.70%
• Largest Region (2024): North America

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: rising occurrence and resurgence of arthropod-borne viral infections, government funding for surveillance infrastructure, and advances in isothermal molecular diagnostics are the primary forces behind the market's expansion, alongside growing demand for rapid arbovirus diagnostics. In April 2024, Grifols received the CE mark under the EU's In Vitro Diagnostic Regulation for its Procleix ArboPlex Assay, an automated nucleic acid test detecting dengue, chikungunya, Zika, and West Nile viruses.

Major Companies Covered: Abbott, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., DiaSorin SpA, Euroimmun AG, F. Hoffmann-La Roche Ltd, QIAGEN N.V., and Thermo Fisher Scientific, Inc., among others.

Segments Covered: By Test Type (ELISA-based Tests, RT-PCR based Tests, Others), By Arboviral Disease (Dengue, Yellow Fever, Zika Virus, West Nile Virus, Chikungunya, Others), By End-use (Hospitals, Diagnostic Centers, Public Health Laboratories, Others), By Region.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/arbovirus-testing-market 

Recent Developments in the Arbovirus Testing Market

• January 2025: The FDA released simplified guidelines for emerging-pathogen IVD clearance, facilitating faster market access for new arbovirus tests.
• April 2024: Grifols received the CE mark for its Procleix ArboPlex Assay, an automated nucleic acid test for dengue, chikungunya, Zika, and West Nile viruses, under the EU's In Vitro Diagnostic Regulation.

Regional Snapshot: North America Leads, Asia Pacific Fastest-Growing

North America generated the largest revenue share in 2024, supported by the rising burden of neglected tropical diseases and growing incidence of West Nile virus, with 2,406 U.S. cases reported by the CDC in 2023, while Asia Pacific is anticipated to register the highest CAGR through 2034 on the back of a large patient pool affected by dengue, yellow fever, and chikungunya. The ELISA-based tests segment held the largest share by test type in 2024, and the dengue segment led by arboviral disease given its substantial global patient burden.

Restraining Factors: Access Gaps and Awareness

Limited awareness of available arbovirus testing facilities in developing countries, combined with restricted access to advanced diagnostic techniques, continues to hold back demand in several regions. Inadequate healthcare infrastructure in under-developed markets is expected to constrain growth over the coming years, even as government-backed surveillance programs expand. In India, for instance, 805 Sentinel Surveillance Hospitals with laboratory support had been established by 2023 to strengthen dengue diagnostic capacity in endemic states.

Technology Shift: Faster Isothermal Molecular Testing

Newer molecular methods that run assays at a constant temperature, negating the need for expensive thermal-cycling equipment, are proving beneficial for market growth. Isothermal amplification now typically takes just 5 to 20 minutes in most cases, a significant improvement over conventional RT-PCR workflows, and is helping diagnostic centers and public health laboratories return results faster during outbreak surges.

Why It Matters for Buyers Evaluating Arbovirus Diagnostic Investments

For stakeholders researching arbovirus testing market forecast trends, the underlying report benchmarks market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034. The World Health Organization's Global Arbovirus Initiative, launched in 2022 to address emerging arboviruses with epidemic and pandemic potential, continues to shape public health procurement priorities across affected regions.

More Trending Latest Reports By Polaris Market Research:

Substation Automation Market

Semiochemicals Market

Material Handling Equipment Market

Protein A, G, and L Resins Market

Semiochemicals Market

Agricultural Robots Market

Polyethylene for Drip Irrigation Pipes Market

Chipotle Salt Market: A Tasteful Ingredient for Seasoning Dishes

Cross-Border B2C E-Commerce Market